Policy changes Backwork has recorded, newest first. The most recent change on record is from October 14, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
83,427 on record
| Recorded | Payer | Policy | Change |
|---|---|---|---|
| Aug 2, 2026 | Independence Blue Cross | Intraoperative Neurophysiological Monitoring (INM) | New policy |
| Aug 2, 2026 | Independence Blue Cross | Interleukin-5 (IL-5) Antagonist (e.g., Cinqair, Exdensur, Nucala) and IL-5 Receptor Antagonist (e.g., Fasenra) | New policy |
| Aug 2, 2026 | Independence Blue Cross | Instrument-Based Vision Screening | New policy |
| Aug 2, 2026 | Independence Blue Cross | Insertion of Implantable Infusion Pumps | New policy |
| Aug 2, 2026 | Independence Blue Cross | Injectable Dermal Fillers for Cosmetic Procedures | New policy |
| Aug 2, 2026 | Independence Blue Cross | Inebilizumab-cdon (Uplizna) | New policy |
| Aug 2, 2026 | Independence Blue Cross | Inclisiran (Leqvio) | New policy |
| Aug 2, 2026 | Independence Blue Cross | Implantable Pulmonary Artery Pressure Sensors for Heart Failure Management | New policy |
| Aug 2, 2026 | Independence Blue Cross | Implantable Cardioverter Defibrillators | New policy |
| Aug 2, 2026 | Independence Blue Cross | Immune Globulin Intravenous (IVIG), Subcutaneous (SCIG) | New policy |
| Aug 2, 2026 | Independence Blue Cross | Immune Cell Function Assay | New policy |
| Aug 2, 2026 | Independence Blue Cross | Imetelstat (Rytelo) | New policy |
| Aug 2, 2026 | Independence Blue Cross | Hyperthermic Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies | New policy |
| Aug 2, 2026 | Independence Blue Cross | Hyperbaric Oxygen Therapy | New policy |
| Aug 2, 2026 | Independence Blue Cross | Hyaluronan Therapies for Osteoarthritis of the Knee | New policy |
| Aug 2, 2026 | Independence Blue Cross | Hospital Readmissions | New policy |
| Aug 2, 2026 | Independence Blue Cross | Hospital Beds and Accessories | New policy |
| Aug 2, 2026 | Independence Blue Cross | Home-Use Light Box for the Treatment of Seasonal Affective Disorder (SAD) | New policy |
| Aug 2, 2026 | Independence Blue Cross | Home Prothrombin Time Monitoring | New policy |
| Aug 2, 2026 | Independence Blue Cross | Home Oxygen Therapy | New policy |
| Aug 2, 2026 | Independence Blue Cross | Home Health Care Services | New policy |
| Aug 2, 2026 | Independence Blue Cross | Home-Based Sleep Studies | New policy |
| Aug 2, 2026 | Independence Blue Cross | High-Technology Radiology Services | New policy |
| Aug 2, 2026 | Independence Blue Cross | High Osmolar Contrast Agents | New policy |
| Aug 2, 2026 | Independence Blue Cross | High-Frequency Chest Wall Oscillation Devices | New policy |
| Aug 2, 2026 | Independence Blue Cross | Hematopoietic Stem Cell Transplantation | New policy |
| Aug 2, 2026 | Independence Blue Cross | Heating Pads and Heat Lamps | New policy |
| Aug 2, 2026 | Independence Blue Cross | Hair Transplants and Cranial Prostheses (Wigs) | New policy |
| Aug 2, 2026 | Independence Blue Cross | Guselkumab (Tremfya) Injection for Intravenous Use | New policy |
| Aug 2, 2026 | Independence Blue Cross | Ground Ambulance Transport Services (Emergency and Nonemergency) | New policy |
| Aug 2, 2026 | Independence Blue Cross | Golimumab (Simponi Aria) Intravenous (IV) Injection | New policy |
| Aug 2, 2026 | Independence Blue Cross | Glofitamab-gxbm (Columvi) | New policy |
| Aug 2, 2026 | Independence Blue Cross | Givosiran (Givlaari) and Panhematin (Hemin) | New policy |
| Aug 2, 2026 | Independence Blue Cross | Full-Body Computerized Tomography (CT) Scan Screening | New policy |
| Aug 2, 2026 | Independence Blue Cross | Filgrastim (Neupogen) and Related Biosimilars, and Tbo-filgrastim (Granix) | New policy |
| Aug 2, 2026 | Independence Blue Cross | Fecal Microbiota Transplantation (FMT) | New policy |
| Aug 2, 2026 | Independence Blue Cross | Fam-trastuzumab deruxtecan-nxki (Enhertu) | New policy |
| Aug 2, 2026 | Independence Blue Cross | Facility Reporting of Observation Services | New policy |
| Aug 2, 2026 | Independence Blue Cross | Eye Prostheses and Scleral Cover Shell | New policy |
| Aug 2, 2026 | Independence Blue Cross | Extraction of Bony Impacted Teeth and Exposure of Impacted Teeth | New policy |
| Aug 2, 2026 | Independence Blue Cross | Extracorporeal Shock Wave Therapy (ESWT) for Musculoskeletal Conditions | New policy |
| Aug 2, 2026 | Independence Blue Cross | External Infusion Pumps | New policy |
| Aug 2, 2026 | Independence Blue Cross | External Breast Prostheses | New policy |
| Aug 2, 2026 | Independence Blue Cross | Experimental/Investigational Services | New policy |
| Aug 2, 2026 | Independence Blue Cross | Evinacumab-dgnb (Evkeeza) | New policy |
| Aug 2, 2026 | Independence Blue Cross | eviCore Lab Management | New policy |
| Aug 2, 2026 | Independence Blue Cross | Evaluation and Treatment of Erectile Dysfunction (ED) | New policy |
| Aug 2, 2026 | Independence Blue Cross | Erythropoiesis Stimulating Agents (ESAs) | New policy |
| Aug 2, 2026 | Independence Blue Cross | Eptinezumab-jjmr (VYEPTI) | New policy |
| Aug 2, 2026 | Independence Blue Cross | Epcoritamab-bysp (EPKINLY) | New policy |